In our study, we explore the potential of a ligand-based strategy to modulate myeloid cell activity within the pancreatic cancer TME, drawing parallels to the effects observed with TREM-1 activation but employing a different mechanism of action in another cancer type. Here, TREM1 is linked to pancreatic neoplasm.